Cargando…
Polycomb Repressive Complex 2 Modulation through the Development of EZH2–EED Interaction Inhibitors and EED Binders
[Image: see text] Epigenetics is nowadays a well-accepted area of research. In the last years, tremendous progress was made regarding molecules targeting EZH2, directly or indirectly. Recently tazemetostat hit the market after FDA-approval for the treatment of lymphoma. However, the impairment of EZ...
Autores principales: | Tomassi, Stefano, Romanelli, Annalisa, Zwergel, Clemens, Valente, Sergio, Mai, Antonello |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404197/ https://www.ncbi.nlm.nih.gov/pubmed/34351144 http://dx.doi.org/10.1021/acs.jmedchem.1c00226 |
Ejemplares similares
-
Depletion of polycomb repressive complex 2 core component EED impairs fetal hematopoiesis
por: Yu, Wenhua, et al.
Publicado: (2017) -
Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED
por: Li, Ling, et al.
Publicado: (2017) -
The Central Role of EED in the Orchestration of Polycomb Group Complexes
por: Cao, Qi, et al.
Publicado: (2014) -
Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer
por: Kim, Woojin, et al.
Publicado: (2013) -
Inhibition of polycomb repressive complex 2 by targeting EED protects against cisplatin‐induced acute kidney injury
por: Yu, Chao, et al.
Publicado: (2022)